Sugi Predict

Sugi Predict / Compounds / SCHEMBL976695

SCHEMBL976695

SCHEMBL976695

Nc1cnc(-c2cccc(Cl)c2Cl)c(N)n1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SCN2A Q99250 2/20 0.62
▸ MAPK1 P28482 2/20 0.59
▸ CYP2D6 P10635 1/20 0.59
▸ MAOA P21397 1/20 0.59
▸ ADRA1A P35348 1/20 0.59
▸ SCN4A P35499 1/20 0.59
▸ BLM P54132 1/20 0.59
▸ PMP22 Q01453 1/20 0.59
▸ PDE3A Q14432 1/20 0.59
▸ SCN5A Q14524 1/20 0.59
▸ SCN9A Q15858 1/20 0.59
▸ SCN3A Q9NY46 1/20 0.59
▸ SCN10A Q9Y5Y9 1/20 0.59
▸ PTPN11 Q06124 18/20 0.58
▸ MAPK3 P27361 1/20 0.54
▸ KCNH2 Q12809 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29542922 0.87 MAPK1 (0.59) SCN2AMAPK1CYP2D6MAOAADRA1A
SCHEMBL7059600 0.87 MAPK1 (0.59) SCN2AMAPK1CYP2D6MAOAADRA1A
SCHEMBL2421429 0.86 SCN2A (0.57) SCN2AMAPK1CYP2D6MAOAADRA1A
SCHEMBL5512633 0.85 SCN2A (0.59) SCN2AMAPK1CYP2D6MAOAADRA1A
SCHEMBL25649854 0.84 PTPN11 (0.62) SCN2AMAPK1CYP2D6MAOAADRA1A
SCHEMBL7061215 0.80 PTPN11 (0.73) SCN2AMAPK1CYP2D6MAOAADRA1A
SCHEMBL28967328 0.80 MAPK1 (0.52) SCN2AMAPK1CYP2D6MAOAADRA1A
SCHEMBL20811241 0.80 PTPN11 (0.56) SCN2AMAPK1CYP2D6MAOAADRA1A
SCHEMBL2416231 0.80 SCN2A (0.48) SCN2AMAPK1CYP2D6MAOAADRA1A
SCHEMBL30502499 0.77 MAPK1 (0.56) SCN2AMAPK1CYP2D6MAOAADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3002280-B1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS UNIV GREENWICH (GB) 2023-05-24 — — EP disclosed
US-9862691-B2 Cyclic triazo and diazo sodium channel blockers UNIVERSITY OF GREENWICH (GB) 2018-01-09 — — US disclosed
US-20160311784-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS UNIVERSITY OF GREENWICH (GB) 2016-10-27 — — US disclosed
US-9422253-B2 Cyclic triazo and diazo sodium channel blockers UNIVERSITY OF GREENWICH (GB) 2016-08-23 — — US disclosed
EP-3002280-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS University of Greenwich (GB) 2016-04-06 — — EP disclosed
US-20140155403-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS UNIVERSITY OF GREENWICH (GB) 2014-06-05 — — US disclosed
CN-101918378-B Cyclic azide and sodium diazoxide channel blockers UNIV GREENWICH 2013-12-04 — — CN disclosed
EP-1945630-B1 PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2011-09-21 — — EP disclosed
EP-1945630-B1 PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2011-09-21 — — EP disclosed
US-20110009413-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS UNIVERSITY OF GREENWICH (GB) 2011-01-13 — — US disclosed
WO-2007052123-A2 PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2007-05-10 — — WO disclosed
WO-2007052123-A2 PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2007-05-10 — — WO disclosed
US-20070105872-A1 N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide PFIZER LIMITED 2007-05-10 — — US disclosed
US-20070105872-A1 N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide PFIZER LIMITED 2007-05-10 — — US disclosed
EP-0966448-B1 PYRAZINE COMPOUNDS GLAXO GROUP LTD (GB) 2003-10-01 — — EP disclosed
US-6599905-B2 Phenyl or naphthyl-pyrazine compounds useful in the treatment of central nervous system diseases SMITHKLINE BEECHAM CORPORATION 2003-07-29 — — US disclosed
US-20020169172-A1 Pyrazine compounds GLAXO WELLCOME INC. 2002-11-14 — — US disclosed
US-6255307-B1 CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS GLAXO WELLCOME, INC. 2001-07-03 — — US disclosed
EP-0966448-A1 PYRAZINE COMPOUNDS GLAXO GROUP LIMITED (GB) 1999-12-29 — — EP disclosed
WO-1998038174-A1 PYRAZINE COMPOUNDS GLAXO GROUP LIMITED (GB) 1998-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155403-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS SCN1A, SCN1B, SCN3A SCN2A 10/4885MAPK1 3993/4885CYP2D6 1326/4885
US-20070105872-A1 N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide P2RX5, P2RX3, AADAC SCN2A 44/4885MAPK1 3278/4885CYP2D6 4/4885
US-20020169172-A1 Pyrazine compounds HCRTR1, HCRTR2, GRIN2C SCN2A 92/4885MAPK1 1501/4885CYP2D6 260/4885
US-20110009413-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS CACNA1E, SCN2B, SCN3A SCN2A 24/4885MAPK1 2697/4885CYP2D6 3472/4885
US-20160311784-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS SCN1A, SCN1B, SCN3A SCN2A 9/4885MAPK1 3755/4885CYP2D6 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.